(71) Applicant (for all designated States except US): MAX-PLANCK-GESELLSCHAFT ZUR FÖRDERUNG DER WISSENSCHAFTEN eV [DE/DE]; Berlin (DE).

(72) Inventors; and
(75) Inventors/Applicants (for US only): BINDER, Elisabeth [AT/DE]; Corneliusstr. 3, 80469 München (DE). HOLSBOER, Florian [CH/DE]; Rohmederstrasse 12, 80805 München (DE). REIN, Theo [DE/DE]; Am Schnepfenweg 60a, 80995 München (DE). WOCHNIK, Gabriele [DE/DE]; Badstr. 15, 86926 Greifenberg (DE). MÜLLER-MYHSOK, Bertram [DE/DE]; Stroblstr. 40, 80689 München (DE). UHR, Manfred [DE/DE]; Föhrenstr. 2, 82131 Stockdork (DE).

(54) Title: FKBP51: A NOVEL TARGET FOR ANTIDEPRESSANT THERAPY

(57) Abstract: The present invention relates to a method of classifying an individual comprising analyzing the nucleic acid of a sample taken from said patient for nucleotide polymorphisms in a haplotype block comprising the gene encoding FKBP51 and/or determining the expression level of FKBP51 in said sample. In a preferred embodiment, the invention provides a method of predicting the response to CC. Furthermore, a method of developing an antidepressant drug, and pharmaceutical compositions are provided.